Evidence map›Paper›PMID 30114201›Full record

ArticlePloS one2018

Strong correlation of lumefantrine concentrations in capillary and venous plasma from malaria patients.

Liusheng Huang, Norah Mwebaza, Richard Kajubi, Florence Marzan, Camilla Forsman, Sunil Parikh, Francesca T Aweeka

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Liusheng HuangDrug Research Unit, Department of Clinical Pharmacy, University of California, San Francisco, CA, United States of America.ORCID 0000-0003-2702-4486
Norah MwebazaDepartment of Pharmacology and Therapeutics, Makerere University College of Health Sciences, Kampala, Uganda.
Richard KajubiInfectious Diseases Research Collaboration, Kampala, Uganda.
Florence MarzanDrug Research Unit, Department of Clinical Pharmacy, University of California, San Francisco, CA, United States of America.
Camilla ForsmanDrug Research Unit, Department of Clinical Pharmacy, University of California, San Francisco, CA, United States of America.
Sunil ParikhDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, United States of America.
Francesca T AweekaDrug Research Unit, Department of Clinical Pharmacy, University of California, San Francisco, CA, United States of America.
University of California, San Francisco · USInfectious Diseases Research Collaboration · UGYale University · US

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 1988 to 2026
$93.6M
The immunologic consequences of prenatal exposure to malariaP01HD059454 · NICHD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAVLIR, DIANE V · 2008 to 2017
$22.6M
Optimizing HIV-malaria treatment in a shifting treatment and resistance landscape in AfricaR01HD068174 · NICHD · YALE UNIVERSITY · PI FRANCESCA T. AWEEKA, SUNIL PARIKH · 2011 to 2026
$8.1M
NIAID NIH HHS P30 AI027763NICHD NIH HHS P01 HD059454NICHD NIH HHS R01 HD068174
6 · The paper itself

Abstract

backgroundLumefantrine is a long-acting antimalarial drug with an elimination half-life of over 3 days and protein binding of 99 percent. Correlation of lumefantrine concentrations from capillary plasma via fingerprick (Cc) versus venous plasma (Cv) remains to be defined.

methodsVenous and capillary plasma samples were collected simultaneously from children, pregnant women, and non-pregnant adults at 2, 24, 120hr post last dose of a standard 3-day artemether-lumefantrine regimen they received for uncomplicated malaria. Some of the enrolled children and pregnant women were also HIV-infected. Samples were analyzed via liquid chromatography tandem mass spectrometry. Linear regression analysis was performed using the program Stata® SE12.1.

resultsIn children, the linear regression equations for Cc vs Cv at 2, 24, and 120hr (day 7) post dose are [Cc] = 1.05*[Cv]+95.0 (n = 142, R2 = 0.977), [Cc] = 0.995*[Cv]+56.7 (n = 147, R2 = 0.990) and [Cc] = 0.958*[Cv]+18.6 (n = 139, R2 = 0.994), respectively. For pregnant women, the equations are [Cc] = 1.04*[Cv]+68.1 (n = 43, R2 = 0.990), [Cc] = 0.997*[Cv]+37.3 (n = 43, R2 = 0.993) and [Cc] = 0.941*[Cv]+11.1 (n = 41, R2 = 0.941), respectively. For non-pregnant adults, the equations are [Cc] = 1.05*[Cv]-117 (n = 32, R2 = 0.958), [Cc] = 0.962*[Cv]+9.21 (n = 32, R2 = 0.964) and [Cc] = 1.04*[Cv]-40.1 (n = 32, R2 = 0.988), respectively. In summary, a linear relationship with a slope of ~1 was found for capillary and venous lumefantrine levels in children, pregnant women and non-pregnant adults at 2hr, 24hr and 120hr post last dose, representing absorption, distribution, and elimination phases.

conclusionsCapillary and venous plasma concentration of lumefantrine can be used interchangeably at 1:1 ratio. Capillary sampling method via finger prick is a suitable alternative for sample collection in clinical studies.

Indexed as

AntimalarialsChildChromatography, LiquidCoinfectionDrug MonitoringFemaleHIV InfectionsHumansLumefantrineMalariaPregnancyTandem Mass SpectrometryTime FactorsAntimalarialsLumefantrine

Identifiers

PMID30114201
PMCPMC6095545
OpenAlexW2886969188

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.